Company: STAA
Filing Date: 2025-10-06
Form Type: DEFA14A
Source: 0001193125-25-230935
Chunk: 5

Company: STAAR SURGICAL CO
Filing Date: 2025-10-06
Form: DEFA14A
Chunk 5
---
 • |     | STAAR’s growth rate has changed significantly since Alcon’s October 2024 offer: |

| • |     | STAAR’s LTM net sales were $261.7 million in the second quarter of 2022 and grew to                                                                                 
 $332.9 million in the second quarter of 2024, which represents a two-year CAGR of 12.8%. This was STAAR’s growth profile when Alcon made its offer in October 2024. |

| • |     | STAAR’s LTM net sales were $305.9 million in the second quarter of 2023 and contracted to                                                                                 
 $224.4 million in the second quarter of 2025, which represents a two-year CAGR of NEGATIVE 14.3%. This was STAAR’s growth profile when Alcon made its offer in July 2025. |

| • |     | STAAR’s long-term prospects have changed due to increased competition in China, among other factors. |

| • |     | While STAAR had been growing net sales at a 25% CAGR from 2020 to 2023, net sales have contracted to a 10% 
 CAGR from 2023 to 2025.                                                                                    |

| • |     | Management’s financial projections for 2026 to 2030, which are subject to these new risks, project 10% net 
 sales growth, which is down sharply from the 25% growth rate that STAAR enjoyed from 2020 to 2023.         |

| 2. | Broadwood allegation: “The intrinsic value of management’s own plan, at an appropriate discount 
 rate, far exceeds $28 per share”                                                                |

| • |     | STAAR Response – Broadwood’s artificially low discount rate is not appropriate given 
 STAAR’s risk profile, and results in an inflated view of STAAR’s long-term value     |

| • |     | STAAR is a single product company that is facing new risks, which justifies a higher discount rate. |

| • |     | Nonetheless, even using Broadwood’s artificially low weighted average cost of capital, the $28 per share 
 offer is in the reference range based on a discounted cash flow analysis valuation.                      |

| 3. | Broadwood allegation: “The price is inadequate and not a reflection of fair value” |

| • |     | STAAR Response – Broadwood continues to be stuck in the past; STAAR’s go